Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 159Leukemia, Myeloid, Acute 141Leukemia, Myelogenous, Chronic, BCR-ABL Positive 67Myeloproliferative Disorders 64Precursor Cell Lymphoblastic Leukemia-Lymphoma 52Primary Myelofibrosis 47Leukemia, Myelomonocytic, Chronic 40Lymphoma, Non-Hodgkin 36Leukemia 26Polycythemia Vera 23Hodgkin Disease 23Myelodysplastic-Myeloproliferative Diseases 21Multiple Myeloma 20Thrombocythemia, Essential 19Hematologic Neoplasms 19Leukemia, Lymphocytic, Chronic, B-Cell 18Neoplasms 17Leukemia, Biphenotypic, Acute 15Anemia, Refractory, with Excess of Blasts 14Sarcoma 13Histiocytosis, Langerhans-Cell 13Glioma 13Neuroblastoma 12Hematologic Diseases 12Wilms Tumor 11Rhabdoid Tumor 11Recurrence 11Osteosarcoma 11Neuroectodermal Tumors, Primitive, Peripheral 11Medulloblastoma 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Polycythemia × Myeloid × 90 days × Clear all
NCT07527221 2026-06-01

Safety and Tolerability of ZE74-0282 in Healthy Volunteers

Eilean Therapeutics

Phase 1 Recruiting
40 enrolled
MyeloidOther hematologic neoplasm

Polycythemia, Thrombocythemia, Essential, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡